These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23390491)

  • 21. [EFFICACY, PHARMACOKINETICS, AND SAFETY OF ICATIBANT FOR THE TREATMENT OF JAPANESE PATIENTS WITH AN ACUTE ATTACK OF HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
    Arerugi; 2018; 67(2):139-147. PubMed ID: 29553114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients.
    Federici C; Perego F; Borsoi L; Crosta V; Zanichelli A; Gidaro A; Tarricone R; Cicardi M
    BMJ Open; 2018 Jul; 8(7):e022291. PubMed ID: 30061443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Icatibant Outcome Survey in Patients with Hereditary Angioedema: Experience in Israel Compared with Other Countries.
    Toubi E; Kivity S; Graif Y; Reshef A; Botha J; Andresen I
    Isr Med Assoc J; 2018 Apr; 20(4):227-232. PubMed ID: 29629730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How satisfactory is on-demand icatibant from the patients' perspective in real life?
    Beyaz S; Demir S; Oztop N; Colakoglu B; Buyukozturk S; Gelincik A
    Allergy Asthma Proc; 2022 Mar; 43(2):148-154. PubMed ID: 35317892
    [No Abstract]   [Full Text] [Related]  

  • 25. Icatibant for the treatment of hereditary angioedema with C1-inhibitor deficiency in adolescents and in children aged over 2 years.
    Farkas H; Kőhalmi KV
    Expert Rev Clin Immunol; 2018 Jun; 14(6):447-460. PubMed ID: 29757016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
    Farkas H; Reshef A; Aberer W; Caballero T; McCarthy L; Hao J; Nothaft W; Schranz J; Bernstein JA; Li HH
    J Allergy Clin Immunol Pract; 2017; 5(6):1671-1678.e2. PubMed ID: 28601641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
    Lumry WR; Li HH; Levy RJ; Potter PC; Farkas H; Moldovan D; Riedl M; Li H; Craig T; Bloom BJ; Reshef A
    Ann Allergy Asthma Immunol; 2011 Dec; 107(6):529-37. PubMed ID: 22123383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).
    Bork K; Frank J; Grundt B; Schlattmann P; Nussberger J; Kreuz W
    J Allergy Clin Immunol; 2007 Jun; 119(6):1497-503. PubMed ID: 17418383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema.
    Wang Y; Jomphe C; Marier JF; Martin P
    J Clin Pharmacol; 2021 Apr; 61(4):555-564. PubMed ID: 33091166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain.
    Guilarte M; Sala-Cunill A; Baeza ML; Cabañas R; Hernández MD; Ibañez E; de Larramendi CH; Lleonart R; Lobera T; Marqués L; de San Pedro BS; Botha J; Andresen I; Caballero T;
    Allergy Asthma Clin Immunol; 2021 Dec; 17(1):137. PubMed ID: 34965883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Self-administration of icatibant in acute attacks of Type I hereditary angioedema: A case report and review of hereditary angioedema.
    Piras V; Alves F; Gonçalo M
    Dermatol Ther; 2019 Nov; 32(6):e13098. PubMed ID: 31579975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
    Cicardi M; Banerji A; Bracho F; Malbrán A; Rosenkranz B; Riedl M; Bork K; Lumry W; Aberer W; Bier H; Bas M; Greve J; Hoffmann TK; Farkas H; Reshef A; Ritchie B; Yang W; Grabbe J; Kivity S; Kreuz W; Levy RJ; Luger T; Obtulowicz K; Schmid-Grendelmeier P; Bull C; Sitkauskiene B; Smith WB; Toubi E; Werner S; Anné S; Björkander J; Bouillet L; Cillari E; Hurewitz D; Jacobson KW; Katelaris CH; Maurer M; Merk H; Bernstein JA; Feighery C; Floccard B; Gleich G; Hébert J; Kaatz M; Keith P; Kirkpatrick CH; Langton D; Martin L; Pichler C; Resnick D; Wombolt D; Fernández Romero DS; Zanichelli A; Arcoleo F; Knolle J; Kravec I; Dong L; Zimmermann J; Rosen K; Fan WT
    N Engl J Med; 2010 Aug; 363(6):532-41. PubMed ID: 20818888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom.
    Longhurst HJ; Dempster J; Lorenzo L; Buckland M; Grigoriadou S; Symons C; Bethune C; Fabien V; Bangs C; Garcez T
    Allergy Asthma Clin Immunol; 2018; 14():28. PubMed ID: 30127805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Icatibant for hereditary angioedema.
    Gras J
    Drugs Today (Barc); 2009 Dec; 45(12):855-64. PubMed ID: 20135020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
    Hide M; Horiuchi T; Ohsawa I; Andresen I; Fukunaga A
    Allergol Int; 2021 Jan; 70(1):45-54. PubMed ID: 32919903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.
    Malbrán A; Riedl M; Ritchie B; Smith WB; Yang W; Banerji A; Hébert J; Gleich GJ; Hurewitz D; Jacobson KW; Bernstein JA; Khan DA; Kirkpatrick CH; Resnick D; Li H; Fernández Romero DS; Lumry W
    Clin Exp Immunol; 2014 Aug; 177(2):544-53. PubMed ID: 24749847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability of disease activity in patients with hereditary angioedema type 1/2: longitudinal data from the Icatibant Outcome Survey.
    Maurer M; Caballero T; Aberer W; Zanichelli A; Bouillet L; Bygum A; Grumach AS; Botha J; Andresen I; Longhurst HJ;
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2421-2430. PubMed ID: 34506666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bradykinin B2 receptor antagonist off label use in short-term prophylaxis in hereditary angioedema.
    Angeletti C; Angeletti PM; Mastrobuono F; Pilotti L; Ciccozzi A; Guetti C
    Int J Immunopathol Pharmacol; 2014; 27(4):653-9. PubMed ID: 25572747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema.
    Straka BT; Ramirez CE; Byrd JB; Stone E; Woodard-Grice A; Nian H; Yu C; Banerji A; Brown NJ
    J Allergy Clin Immunol; 2017 Jul; 140(1):242-248.e2. PubMed ID: 27913306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial.
    Baş M
    Expert Rev Clin Immunol; 2012 Nov; 8(8):707-17. PubMed ID: 23167682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.